Bibliographic Citation
| - Baas Paul, Scherpereel Arnaud, Nowak Anna, Fujimoto Nobukazu, Peters Solange, Tsao Anne, Mansfield Aaron, Popat Sanjay, Jahan Thierry, Antonia Scott, Oulkhouir Youssef, Bautista Yolanda, Cornelissen Robin, Greillier Laurent, Grossi Francesco, Kowalski Dariusz, Rodríguez-Cid Jerónimo, Aanur Praveen, Oukessou Abderrahim, Baudelet Christine, Zalcman Gérard . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial . The Lancet Digital Health, 2021, 397 (10272), pp.375-386 . ⟨10.1016/S0140-6736(20)32714-8⟩
- Baas Paul, Scherpereel Arnaud, Nowak Anna, Peters Solange, Tsao Anne, Mansfield Aaron, Popat Sanjay, Jahan Thierry, Antonia Scott, Oulkhouir Youssef, Bautista Yolanda, Cornelissen Robin, Greillier Laurent, Grossi Francesco, Kowalski Dariusz, Rodríguez-Cid Jerónimo, Aanur Praveen, Oukessou Abderrahim, Baudelet Christine, Zalcman Gérard. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet Digital Health, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩
|